Medical Advocates
HIV/TB Coinfection
  Drugs

 General Reports   
Antiretrovirals: General
Cotrimoxazole
Efavirenz
Isoniazid
 Nelfinavir
 Nevirapine
 Pyrazinamide
Rifabutin
Rifampin
Rifamycins: General Reports
Zidovudine
 
HIV/TB Treatment HIV/TB Main Page  Home Page
Last Update:  November 25, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
     
     Internet Documents
 
  FULL TEXT PDF DOCUMENT
 Updated Guidelines for Managing Drug Interactions in the Treatment of
HIV-Related Tuberculosis
US CDC
February 01, 2008
 Guidelines

     Journal Papers, Abstracts, and Commentaries
 
 
Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery.
Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ. 
Drug Discov Today. 2007 Nov;12(21-22):980-989.
Abstract

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with
advanced human immunodeficiency virus disease.
Gurumurthy P, Ramachandran G, Hemanth Kumar A
Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5.
 Abstract
Antiretrovirals/HAART: General Reports
     

     Internet Reports

 

FULL-TEXT DOCUMENT
 Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among
HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase
Inhibitors
CDC Web Site
Updated January 20, 2004
 Guidelines

     Journal Papers, Abstracts, and Commentaries

 
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in
TB/HIV type 1-coinfected patients.
Sathia L, Obiorah I, Taylor G, et al  
AIDS Res Hum Retroviruses. 2008 Jul;24(7):897-901.
 Abstract
 
Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the
introduction of HAART.
Muga R, Ferreros I, Langohr K, et al 
AIDS. 2007 Nov 30;21(18):2521-2527.
 Abstract
 
Timing of Antiretroviral Therapy Initiation in Tuberculosis Patients With AIDS:
A Decision Analysis.
Schiffer JT, Sterling TR.
J Acquir Immune Defic Syndr. 2006 Dec 7
 Abstract
 
Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and
Without Antiretroviral Therapy.
Manosuthi W, Chottanapand S, Thongyen S, et al  
 J Acquir Immune Defic Syndr. 2006 Jul 31
 Abstract
 
Antiretroviral therapy and TB.
Swaminathan S, Luetkemeyer A, Srikantiah P, et al
Trop Doct. 2006 Apr;36(2):73-9.
Abstract
 
Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.
Di Perri G, Aguilar Marucco D, et al  
Expert Opin Drug Saf. 2005 Sep;4(5):821-36.
 Abstract
 
How effectively does HAART restore immune responses to Mycobacterium tuberculosis?
Implications for tuberculosis control.
Lawn SD, Bekker LG, Wood R. 
AIDS. 2005 Jul 22;19(11):1113-1124.
 Abstract
 
Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical
experiences from Thailand.
Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A.
J Infect. 2005 Jun 28;
Abstract
 
Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
Kwara A, Flanigan TP, Carter EJ. et al   
Int J Tuberc Lung Dis. 2005 Mar;9(3):248-57.
 Abstract

WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral
treatment: relationship to CD4 lymphocyte counts.
Teck R, Ascurra O, Gomani P, Manzi M, et al
Int J Tuberc Lung Dis. 2005 Mar;9(3):258-62.
 Abstract

Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
Kwara A, Flanigan TP, Carter EJ.
 Int J Tuberc Lung Dis. 2005 Mar;9(3):248-57
 Abstract

Acute Renal Failure on Immune Reconstitution in an HIV-Positive Patient with Miliary
Tuberculosis
Jehle AW, Khanna N, Sigle JP, et al 
Clin Infect Dis. 2004 Feb 15;38(4):E32-E35
 Abstract
 

     Conference Reports, Abstracts, and Posters

 
HIV/TB: when is it safe to start HAART?
R WoodNinth
(International Congress on Drug Therapy in HIV Infection)
PDF Abstract
 

POWERPOINT POSTER PRESENTATION
Risk factors for tuberculosis within 3 months of HAART initiation
T Sterling
(XVII International AIDS Conference)
 Poster Presentation
 
Altered Clinical Manifestation of Tuberculosis (TB) in HIV-infected persons receiving highly active
antiretroviral therapy (HAART)
 A.C.K. Chan, F.A. Bognar, I.K.Y. Mak, et al
(XVII International AIDS Conference)
Abstract
 
Response to HAART in naïve patients with a diagnosis of tuberculosis
 S. Moreno, P. Sobrino, A.M. Caro Murillo, et al
(XVII International AIDS Conference)
Abstract

Incidence of adverse events during tuberculosis therapy in patients with and without HIV
co-infection
 Pereira RL, Velasque L, Brasil PEA, et al
 (4th IAS Conference)
 Abstract
Cotrimoxazole
     

     Journal Papers, Abstracts, and Commentaries

  Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.
Zachariah R, Massaquoi M.   
Trop Doct. 2006 Apr;36(2):79-82.
Abstract
 
     Conference Reports, Abstracts, and Posters
 
  Impact of antiretroviral therapy and cotrimoxazole preventive therapy on survival of HIV-infected patients with
tuberculosis – Cambodia, 2007
 R. Song, T. Heller, E. Bunthoeun, et al
 (XVII International AIDS Conference)
 Abstract
 
Progress in implementation of cotrimoxazole prophylaxis and isoniazid preventive therapy policies for
HIV-infected people in HIV and TB/HIV high-burden countries
 M. Vitoria, A. Date, R. Granich, et al
 (XVII International AIDS Conference)
 Abstract
Efavirenz
     

     Journal Papers, Abstracts, and Commentaries

  Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels
but excellent clinical outcomes in patients treated for tuberculosis and HIV.
 Friedland G, Khoo S, Jack C, Lalloo U.  
J Antimicrob Chemother. 2006 Oct 10;
Abstract
 
Efavirenz trough levels are not associated with virological failure throughout therapy
with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al
J Antimicrob Chemother. 2006 Sep 6;
 Abstract
 
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving
rifampicin: 48 weeks results.
Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al
AIDS. 2006 Jan 2;20(1):131-132.
 Abstract

     Conference Reports, Abstracts, and Posters

  TB co-infection treated at onset of therapy does not affect long-term risk of treatment failure among
HIV-1 patients initiating efavirenz (EFV)-based combination antiretroviral treatment (cART)
 Patel K, Patel A, Naik E, et al
 (4th IAS Conference)
 Abstract
Isoniazid
     

     Journal Papers, Abstracts, and Commentaries

  Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
Gurumurthy P, Ramachandran G, Hemanth Kumar AK ,et al
Clin Infect Dis. 2004 Jan 15; 38(2): 280-3
 Abstract
 
Isoniazid associated, painful, bilateral gynaecomastia.
Khanna P, Panjabi C, Maurya V, Shah A.
Indian J Chest Dis Allied Sci. 2003 Oct-Dec; 45(4): 277-9
 Abstract

     Conference Reports, Abstracts, and Posters

 
Isoniazid preventative therapy and screening for TB: the need to move from policy to action
 C. Gunneberg, M. Hosseini, S. Scheele, et al
 (XVII International AIDS Conference)
 Abstract

The effectiveness of HAART and isoniazid preventive treatment (IPT) in preventing TB in
HIV-infected adults - a prospective cohort from two South African sites
 Golub J, Pronyk P, McIntyre JA,  et al
(4th IAS Conference)
 Abstract
Nelfinavir
     

     Journal Papers, Abstracts, and Commentaries

  Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and
human immunodeficiency virus infection.
Benator DA, Weiner MH, Burman WJ, et al
Pharmacotherapy. 2007 Jun;27(6):793-800.
 Abstract
Nevirapine
     

     Journal Papers, Abstracts, and Commentaries

  Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of
nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
 Manosuthi W, Ruxrungtham K, Likanonsakul S, et al
Clin Infect Dis. 2007 Jan 1;44(1):141-4.
 Abstract
 
Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin
Coadministration.
 Ramachandran G, Hemanthkumar AK, Rajasekaran S,  
Acquir Immune Defic Syndr. 2006 Apr 24;
Abstract

    Conference Reports, Abstracts, and Posters

  24-week efficacy and safety of nevirapine: 400 mg versus 600 mg based HAART in
HIV-infected patients with active tuberculosis receiving rifampicin
 Manosuthi W, Avihingsanon A, Kantipong P, et al
 (4th IAS Conference)
 Abstract
Pyrazinamide
     

     Journal Papers, Abstracts, and Commentaries

  The Clinical Pharmacokinetics of Pyrazinamide in HIV-Infected Persons with
Tuberculosis.
Perlman DC, Segal Y, Rosenkranz S, et al 
Clin Infect Dis. 2004 Feb 15;38(4):556-564
 Abstract
Rifamycins: General Reports
     

     Internet Reports

 

FULL-TEXT DOCUMENT
 Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among
HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase
Inhibitors
CDC Web Site
Updated January 20, 2004
 Guidelines

     Journal Papers, Abstracts, and Commentaries

 
Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and
low-dose ritonavir in HIV-infected patients with tuberculosis.
 Ribera E, Azuaje C, Lopez RM, et al
J Antimicrob Chemother. 2007 Feb 16;
 Abstract
 
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy
volunteers.
Burger DM, Agarwala S, Child M
Antimicrob Agents Chemother. 2006 Oct;50(10):3336-42.
 Abstract
 
Acquired Rifamycin-resistance with Twice-weekly Treatment of HIV-related Tuberculosis.
Burman W, Benator D, Vernon A, et al
Am J Respir Crit Care Med. 2005 Aug 18
 Abstract
 
FULL-TEXT PDF DOCUMENT
Rifamycin Dosing in TB/HIV Co-infection
IDCR  March 2006
 PDF Paper
 
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin
and isoniazid among patients with HIV and tuberculosis.
Weiner M, Benator D, Burman W  
Clin Infect Dis. 2005 May 15;40(10):1481-91.
Abstract

FULL-TEXT ARTICLE
Acquired Rifamycin Resistance in Persons with Advanced HIV Disease Being
Treated for Active Tuberculosis with Intermittent Rifamycin-Based Regimens
MMWR 2002 March 15;51(10):214-5
 Paper
Rifabutin
     

     Journal Papers, Abstracts, and Commentaries

 
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and
human immunodeficiency virus infection.
Benator DA, Weiner MH, Burman WJ, et al
Pharmacotherapy. 2007 Jun;27(6):793-800.
 Abstract
 
Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with
rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J, Munsiff SS, Driver CR, Sackoff J.  
Clin Infect Dis. 2005 Jul 1;41(1):83-91.
 Abstract

FULL-TEXT ARTICLE
Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and
Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors
or Nonnucleoside Reverse Transcriptase Inhibitors
MMRW 2000 Mar 10; 49(09);185-9
 Paper

     Conference Reports, Abstracts, and Posters

  PK analysis of rifabutin given with lopinavir/ritonavir to persons co-infected with TB and HIV
 Boulanger C, Peloquin C, Hollender E, et al
(4th IAS Conference)
 Abstracts
Rifampin
     

     Journal Papers, Abstracts, and Commentaries

 
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels
but excellent clinical outcomes in patients treated for tuberculosis and HIV.
 Friedland G, Khoo S, Jack C, Lalloo U.  
J Antimicrob Chemother. 2006 Oct 10;
Abstract
 
Efavirenz trough levels are not associated with virological failure throughout therapy
with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al
J Antimicrob Chemother. 2006 Sep 6;
 Abstract
 
Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with
rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J, Munsiff SS, Driver CR, Sackoff J.  
Clin Infect Dis. 2005 Jul 1;41(1):83-91.
 Abstract
 
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with
advanced human immunodeficiency virus disease.
Gurumurthy P, Ramachandran G, Hemanth Kumar A
Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5.
 Abstract
 
Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis
Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons?
Gordin FM, Cohn DL, Matts JP,  et al
Clin Infect Dis. 2004 Aug 15;39(4):561-5. 15;39(4):561-5
 Abstract
 
Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose
ritonavir in HIV-infected patients.
Justesen US, Andersen AB, Klitgaard NA 
Clin Infect Dis. 2004 Feb 1; 38(3): 426-9.
 Abstract

Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
Gurumurthy P, Ramachandran G, Hemanth Kumar AK ,et al
Clin Infect Dis. 2004 Jan 15; 38(2): 280-3
 Abstract
 
Zidovudine
     

     Conference Reports, Abstracts, and Posters

  Generic AZT vs d4T In HIV/TB Co-infection in Clinical Practice In India: An
Observational Study
 D Saple,  S Vaidya  
 (11 CROI)
 Abstract

HIV/TB Treatment HIV/TB Main Page  Home Page

HIV /Tuberculosis Drugs